FindTrial
Sign In

A clinical trial to study the effect of N-acetyl cysteine (NAC)in patients with pulmonary tuberculosis

The role of N-acetyl cysteine in patients with newly detected sputum positive pulmonary tuberculosis, a double blind randomised control trial

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2007/091/000012
Enrollment
Unknown
Registered
2007-09-24
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: N-acetyl cysteine: 600 mg once daily, dissolved in 200 ml water and administered orally. Control Intervention1: Placebo: once daily, dissolved in 200 ml water and administered orally.

Sponsors

Christian Medical College - Vellore
Lead Sponsor
Tuberculosis Control India - RNTCP
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Adult males or females who completed 18 years,detected to have sputum positive pulmonary tuberculosis, willing to take Anti tuberculous treatment under RNTCP - DOTS strategy

Exclusion criteria

Exclusion criteria: 1) Co-existing chronic lung disease, 2) Pregnancy, 3) Patients not willing to enroll in DOTS, 4) Anemia other than nutritional anemia.

Design outcomes

Primary

MeasureTime frame
Sputum smear conversion rateTimepoint: 1 month after the start of treatment;Sputum smear conversion rateTimepoint: 15 days—

Secondary

MeasureTime frame
Cure rate and relapse rateTimepoint: 2nd, 4th and 6th month after the start of treatment—

Countries

India

Contacts

Public ContactDr. Dhanasekar. K.R
dhanasekar.kr@gmail.com0416-2284237

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026